Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 9/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.44 |
| ▸ | SMO | Q99835 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14818958 | 0.86 | GBA1 (0.63) | GBA1EPHX2ALDH1A1KMT2AMEN1 | |
| SCHEMBL12069781 | 0.85 | MAPT (0.48) | SMOMAPTSMN1; SMN2ALDH1A1KMT2A | |
| SCHEMBL14804471 | 0.83 | MAPT (0.40) | GBA1SMOMAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL24654627 | 0.76 | ALDH1A1 (0.61) | GBA1EPHX2MAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL12500191 | 0.74 | EPHX2 (0.50) | EPHX2MAPTSMN1; SMN2ALDH1A1KMT2A | |
| SCHEMBL14818929 | 0.74 | KMT2A (0.64) | MAPTSMN1; SMN2ALDH1A1KMT2AMEN1 | |
| SCHEMBL14818930 | 0.73 | EPHX2 (0.42) | GBA1EPHX2SMN1; SMN2ALDH1A1KMT2A | |
| SCHEMBL18153409 | 0.72 | GALR2 (0.54) | GBA1MAPTSMN1; SMN2KMT2AMEN1 | |
| SCHEMBL12069783 | 0.71 | GBA1 (0.48) | GBA1SMOMAPT | |
| SCHEMBL14818970 | 0.70 | P2RY12 (0.43) | MAPTSMN1; SMN2KMT2AMEN1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8623857-B2 | N-phenyl imidazole carboxamide inhibitors of 3-phosphoinositide-dependent protein kinase-1 | MERCK SHARP & DOHME CORP. (US) | 2014-01-07 | — | — | US | disclosed |
| US-20130079326-A1 | N-PHENYL IMIDAZOLE CARBOXAMIDE INHIBITORS OF 3-PHOSPHOINOSITIDE-DEPENDENT PROTEIN KINASE-1 | MERCK SHARP & DOHME CORP. | 2013-03-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130079326-A1 | N-PHENYL IMIDAZOLE CARBOXAMIDE INHIBITORS OF 3-PHOSPHOINOSITIDE-DEPENDENT PROTEIN KINASE-1 | PDPK1, PDK1, PDK3 | GBA1 4030/4885EPHX2 4687/4885SMO 1724/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.